Enzyme Produces Product Which Is Part Of Another Reaction System (e.g., Cyclic Reaction, Cascade Reaction, Etc.) Patents (Class 435/7.91)
  • Patent number: 7198904
    Abstract: A panel of monoclonal antibodies recognizing and binding to human inducible nitric oxide synthase (iNOS or type II iNOS) enzyme have been developed. The monoclonal antibodies may also be employed in an assay to detect the presence and/or quantitate the amount of human iNOS.
    Type: Grant
    Filed: April 7, 1997
    Date of Patent: April 3, 2007
    Inventor: Robert Webber
  • Patent number: 7186502
    Abstract: Processes for preparing controlled samples of particles, including microorganisms and cells are described. A sample of particles is provided and separated into a predetermined number of desired particles by particle separation means. The predetermined number of particles is dispensed into a receptacle or onto a surface in accordance with a sorting instruction, with the receptacle or surface being positioned by collecting means so as to receive the dispensed particles. A sorting instruction from the particle dispensing means activates the collecting means such that when a sorting instruction has been actuated, so as to deliver a predetermined number of particles into a receptacle or onto a surface which is positioned accurately for sufficient time to collect all sorted particles, the collecting means advances and positions a subsequent surface or receptacle for receipt of particles, the collector means thereafter signaling the particle separation means to commence the next sorting instruction.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: March 6, 2007
    Assignee: BTF Pty, Ltd.
    Inventor: Graham Vesey
  • Patent number: 7183119
    Abstract: The present invention relates to a method of detecting biological analytes comprising suspending a target analyte in a suspending solution containing polymeric particles marked with a probe, wherein the probe has an affinity for said target analyte; adding recognition unit-peroxidase conjugate marker to the suspending solution; forming a complex of the target analyte, the polymeric particles marked with a probe, and the recognition unit-peroxidase conjugate marker; contacting a gelatin surface with the suspending solution; adding developer to the suspending solution in contact with the gelatin surface in the presence of phenol to attach the complex to the gelatin surface; washing the gelatin surface; and detecting the complex attached to the gelatin surface.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: February 27, 2007
    Assignee: Eastman Kodak Company
    Inventors: Tiecheng A. Qiao, Brian J. Kelley
  • Patent number: 7138504
    Abstract: The invention teaches derivatives of mycophenolic alcohol and methods of preparing immunogens and other conjugates useful in immunoassays for quantitatively measuring concentrations of mycophenolic acid (MPA) and/or active metabolites of MPA in patient specimens. Antibodies produced from the disclosed immunogens capable of binding to MPA with cross-reactivity of no more than 5% with inactive metabolites and commonly co-prescribed drugs. Further, immunoassays for measuring the concentration of MPA using such antibodies are taught.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: November 21, 2006
    Assignee: Microgenics Corporation
    Inventors: Vani B. Bodepudi, Amy P. Tsai, Weixing Luo, Rueyming Loor
  • Patent number: 7135298
    Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: November 14, 2006
    Assignee: The Burnham Institute for Medical Research
    Inventor: Robert T. Abraham
  • Patent number: 7135304
    Abstract: Test system for the determination of in-vivo active hemostasis proteases or of trypsin or subtilisin in biological fluids and the usage thereof to determine the in-vivo activation of hemostasis or to diagnose pancreatitis.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: November 14, 2006
    Inventor: Thomas W. Stief
  • Patent number: 7132245
    Abstract: The application discloses markers associated with organ transplant rejection and associated conditions, and in particular provides materials and methods for the diagnosis, prognosis or treatment of chronic rejection of transplanted organ such as heart and kidney. Examples of the markers include ribosomal protein L7, ?-transducin, 1-TRAF (also known as TANK) or lysyl-tRNA synthetase, or antibodies against these antigens.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: November 7, 2006
    Assignee: Imperial Innovation Limited
    Inventors: Marlene Lydia Rose, Michael John Dunn, Adam Linke
  • Patent number: 7112408
    Abstract: The present invention is directed to a method for determining whether a woman has, or is likely to develop, ovarian cancer based upon assays of the alpha subunit of haptoglobin.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: September 26, 2006
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Bin Ye, Samuel C. Mok, Daniel W. Cramer, Ross S. Berkowitz, Steven Skates
  • Patent number: 7105307
    Abstract: The invention provides a method to screen for a modulator of enzymatic activity comprising the step of monitoring the association or dissociation of a pair of polypeptides which can associate as a dimer. The polypeptide pair comprises a first polypeptide comprising detection means and a site of post-translational modification and a second polypeptide comprising detection means.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: September 12, 2006
    Assignee: Cyclacel, Ltd.
    Inventors: John Colyer, Derek N. Woolfson, Joanne Lightowler
  • Patent number: 7101682
    Abstract: Methods, compositions and kits are disclosed. The methods are directed to determining the presence of one or more analytes in a sample suspected of containing any one of a plurality of the analytes. A combination is provided comprising in a medium (i) the sample, (ii) a binding partner for each of the analytes, (iii) for each of the analytes, a first reagent comprising a member of a signal producing system, a ligand and an analyte analog, and (iv) a second reagent comprising a binding partner for the ligand. The binding of the binding partner for the ligand is affected by the presence of an analyte and alters the amount of signal produced by the member of the signal producing system. The signal thus is modulated if one or more of the analytes are present in the sample. The amount of the signal is determined and is related to the presence of one or more of the analytes in the sample. The method may be homogeneous or heterogeneous.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: September 5, 2006
    Assignee: Dade Behring Marburg GmbH
    Inventors: Edwin F. Ullman, Marcel Pirio, Mary C. Ericson, Daniel B. Wagner, Dariush Davalian
  • Patent number: 7074622
    Abstract: The present invention relates to a method of particle separation comprising preparing a suspension of particles containing at least one recognizable target particle in a suspending solution, labeling the target particle with a conjugate marker, wherein the conjugate marker comprises at least one recognition unit for the recognizable target particle and at least one peroxidase enzyme, contacting a gelatin surface with the suspending solution, adding developer to the suspending solution in contact with the gelatin surface and in the presence of phenol to attach the target particle to the gelatin surface, and washing the gelatin surface to remove unattached particles. The method may also include detecting the presence of the target particle on the gelatin surface as well as detaching and recovering the attached particles after removal of the non-target particles.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: July 11, 2006
    Assignee: Eastman Kodak Company
    Inventors: Tiecheng A. Qiao, Yun C. Chang, Eric R. Schmittou, Thomas I. Penner
  • Patent number: 7053249
    Abstract: ?-diketone fluorescent tags are disclosed, particularly those enabling the use of excitation energy in the near visible or visible spectrum. In some cases, these tags allow the use of cost-effective excitation devices such as LED's. The compounds form fluorescent chelates (complexes) with lanthanide (III) rare earth metal ions (such as Eu3+). The fluorescent complex may be included in a latex microparticle, such as a styrene latex particle. Ideally, the complex has an absorption maximum ? equal to or greater than 360 nm, and the compound is characterized by a pKa<9.0. Kits and methods for detecting target molecules (e.g. immunoassays) are also disclosed. Such methods and kits typically use a ligand for binding to the target molecule and a labeling agent attached to the ligand. The fluorescent complexes described above are at least part of the labeling agent.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: May 30, 2006
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Yerramilli Murthy, Robert H. Suva
  • Patent number: 7033775
    Abstract: Methods, compositions and kits are disclosed. The methods are directed to determining the presence of one or more analytes in a sample suspected of containing any one of a plurality of the analytes. A combination is provided comprising in a medium (i) the sample, (ii) a binding partner for each of the analytes, (iii) for each of the analytes, a first reagent comprising a member of a signal producing system, a ligand and an analyte analog, and (iv) a second reagent comprising a binding partner for the ligand. The binding of the binding partner for the ligand is affected by the presence of an analyte and alters the amount of signal produced by the member of the signal producing system. The signal thus is modulated if one or more of the analytes are present in the sample. The amount of the signal is determined and is related to the presence of one or more of the analytes in the sample. The method may be homogeneous or heterogeneous.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: April 25, 2006
    Assignee: Dade Behring Marburg GmbH
    Inventors: Edwin F. Ullman, Marcel Pirio, Mary C. Ericson, Daniel B. Wagner, Dariush Davalian
  • Patent number: 7022493
    Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: April 4, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
  • Patent number: 7018523
    Abstract: The invention relates to novel methods and compositions for the detection of analytes using the nuclear reorganization energy, ?, of an electron transfer process.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: March 28, 2006
    Assignee: Clinical Micro Sensors, Inc.
    Inventor: Thomas J. Meade
  • Patent number: 7005271
    Abstract: The present invention relates to determining the prethrombotic state, in particular determining an amount or presence of circulating microparticles and/or stimulated procoagulant cells.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: February 28, 2006
    Inventors: Jean-Marie Freyssinet, Benedicte Antoni, Frederic Donie, Helmut Lill
  • Patent number: 7001739
    Abstract: The present invention includes a method for detecting and isolating sugarcane proteins that interact with the HC-Pro and P1 proteins of SrMV and other proteins involved in gene silencing, particularly in sugarcane. The method uses a two hybrid assay with an HC-Pro, P1, or other silencing-related protein-containing bait protein and a prey protein containing a polypeptide encoded by a DNA molecule in a cDNA library. The method also includes identification of false positives through reverse two-hybrid assays and using in vitro techniques such as farwestern blots or pull down assays where plant physiological conditions may be replicated. Finally, interactions may be confirmed in planta. Some novel proteins used in and discovered using the these methods are also identified. Methods of using viral and plant proteins to regulate silencing in plants such as sugarcane are also discussed.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: February 21, 2006
    Assignee: The Texas A&M University System
    Inventors: T. Erik Mirkov, Ivan L. Ingelbrecht
  • Patent number: 6994980
    Abstract: A novel chemiluminescent compound is provided. In one embodiment, the novel compound is employed in an assay to detect analytes. The assay to detect analytes includes the steps of binding the novel compound to the analyte and detecting the novel compound.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: February 7, 2006
    Assignee: Quest Diagnostics Investments Inc.
    Inventors: Phillip P. Miller, Martha Garrity
  • Patent number: 6984494
    Abstract: The instant invention describes an analytical assay to accurately measure an analyte in the presence of an interfering substance.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: January 10, 2006
    Assignee: Genentech, Inc.
    Inventor: Peter Ralph
  • Patent number: 6979551
    Abstract: Provided are methods and compositions for assaying for ubiquitin agents that are enzymatic components of ubiquitin-mediated proteolysis and, more particularly, methods and compositions for assaying for agents that modulate the activity of such ubiquitin agents.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: December 27, 2005
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
  • Patent number: 6969584
    Abstract: The invention relates to the formation of novel in vivo combinatorial enzyme complexes for use in screening candidate drug agents for bioactivity.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: November 29, 2005
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Garry P. Nolan, Donald Payan
  • Patent number: 6964872
    Abstract: When insoluble magnetic carrier particles are used in immunoassay, a method is provided which is suitable for saving labor and for treating a large number of samples within a short time while avoiding problems including difficulties in the stability of sensitized insoluble magnetic particles and in their preparation. In assaying an antigenic substance in test samples, no use is made of insoluble magnetic particles carrying an antibody specific to the said antigenic substance but insoluble magnetic carrier particles are provided in a state free from adsorbing said antibody, etc. Then the antigenic substance per se to be assayed is adsorbed on the insoluble magnetic carrier particles followed by reaction with a labeled antibody specific to the said adsorbed antigenic substance. Thus, the antigenic substance in the test sample can be efficiently assayed in a mode suitable for automation.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: November 15, 2005
    Assignee: SRL, Inc.
    Inventors: Masaaki Sakurai, Naoki Takanashi, Masanori Oka, Minoru Hirata
  • Patent number: 6955886
    Abstract: The invention provides a scintillation proximity assay for detecting peptidoglycan synthesis. The assay is especially suitable for high throughput screening of compounds affecting peptidoglycan synthesis.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: October 18, 2005
    Assignee: AstraZeneca AB
    Inventors: Sunita Desousa, Dwarakanath Prahlad
  • Patent number: 6939720
    Abstract: A method for the multiplexed diagnostic and genetic analysis of enzymes, DNA fragments, antibodies, and other biomolecules comprises the steps of constructing an appropriately labeled beadset, exposing the beadset to a clinical sample, and analyzing the combined sample/beadset by flow cytometry. Flow cytometric measurements are used to classify, in real-time, beads within an exposed beadset and textual explanations, based on the accumulated data obtained during real-time analysis, are generated for the user. The inventive technology enables the simultaneous, and automated, detection and interpretation of multiple biomolecules or DNA sequences in real-time while also reducing the cost of performing diagnostic and genetic assays.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: September 6, 2005
    Assignee: Luminex Corporation
    Inventors: Van S. Chandler, R. Jerrold Fulton, Mark B. Chandler
  • Patent number: 6936429
    Abstract: The present invention provides an assay for an analyte in solution. The assay relies, in part, on associating two catalytic activities in close proximity to each other (e.g., by conjugating each enzyme to a ligand that binds the analyte) and providing substrates that produce a colored product only when both activities are bound to the same molecule in solution.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: August 30, 2005
    Assignee: Chronomed, Inc.
    Inventor: Alex M. Saunders
  • Patent number: 6933123
    Abstract: An isolated protein sequence or peptide from the E2, E6 or E7 early coding region of human papillomavirus (HPV) that is soluble in an aqueous medium, and characterized by a relative paucity of tryptophan, methionine and cysteine residues, and a relative abundance of glycine and asparagine residues. Also disclosed are isolated protein sequences or peptides from the E2, E6 or E7 early coding regions of HPV 16 and 18 and methodologies for detecting or diagnosing cancer or cellular abnormalities. Detection or diagnosis of Cancer or cellular abnormalities may include detecting or diagnosing pre-cancerous or pre-malignant conditions, cervical dysplasia, cervical carcinoma, koilocytosis, hyperkeratosis, intraepithelial lesions, and other cancers.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 23, 2005
    Inventors: Yao Xiong Hu, Mark J. Rosenfeld
  • Patent number: 6919184
    Abstract: Provided are methods and compositions for assaying for ubiquitin agents that are enzymatic components of ubiquitin-mediated proteolysis and, more particularly, methods and compositions for assaying for agents that modulate the activity of such ubiquitin agents.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: July 19, 2005
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
  • Patent number: 6913895
    Abstract: This invention relates to the field of bacterial transglycosylase reactions. The invention is directed to methods for assaying for transglycosylase activity, methods of identifying inhibitors of transglycosylase activity, inhibitors identified by such methods, and methods of identifying the stage of inhibition at which such inhibitors act.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: July 5, 2005
    Assignee: Advanced Medicine East, Inc.
    Inventors: Robert C. Goldman, Arthur A. Branstrom
  • Patent number: 6913935
    Abstract: A method for the assay of N samples each containing a compound to be tested, comprises providing N reaction vessels each containing a population of carrier beads and other reagents for performing the assay, where N is at least 2 e.g. 80-4000. Each population of carrier beads is distinguishable from every other population. After adding the samples to the reaction vessels and performing the assays, the contents of all the reaction vessels are mixed and subjected to analysis by flow cytometry. By means of flow cytometry, each carrier bead is rapidly analysed to identify its population and also to determine the presence or concentration or biological activity of the compound to be tested.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: July 5, 2005
    Assignee: Amersham Biosciences UK Limited
    Inventor: Nicholas Thomas
  • Patent number: 6911316
    Abstract: Methods of using a complex (scuPA/suPAR) which has thrombolytic activity under physiological conditions and in the presence of IgG, or of at least one IgG-derived peptide, which complex comprises a single chain urokinase type plasminogen activator (scuPA) and a soluble urokinase plasminogen activator receptor (suPAR), for the treatment and/or prevention of thromboembolic disorders associated with the formation of fibrin clots are disclosed.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: June 28, 2005
    Assignee: Thrombotech Ltd.
    Inventor: Abd Al-Roof Higazi
  • Patent number: 6900291
    Abstract: The present invention relates to methods and materials for the detection and quantitation 8-OH-Ade in biological specimens. Specifically, the present invention is directed to a group of highly specific monoclonal antibodies reactive with the modified nucleoside structure 8-OH-Ade, and to various immunoassays for 8-OH-Ade utilizing these monoclonal antibodies. The monoclonal antibodies of the present invention may be used in assays for diagnosing or monitoring the progression of certain types of cancer, in addition to a variety of other diseases associated with mutagenesis resulting from oxidative damage of DNA. Assays utilizing the monoclonal antibodies of the present invention may also be used to analyze or monitor toxicant exposure, such as from environmental sources. The monoclonal antibodies of the present invention were prepared with the immunogen 8-OH-adenosine coupled to keyhole limpet hemocyanin (KLH), not to 8-OH-Ade directly.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: May 31, 2005
    Assignee: CytoChem, Inc.
    Inventors: Eric H. Holmes, Thomas G. Greene
  • Patent number: 6893825
    Abstract: A microorganism mixture consisting of a first microorganism that secretes a substance upon perception of an environmental factor and a second microorganism that expresses a marker gene upon perception of the secreted substance is disclosed. The present invention provides a means for measuring environmental factors, such as osmotic pressure, simply and with high accuracy.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: May 17, 2005
    Assignee: Riken
    Inventors: Hitoshi Sakakibara, Kentaro Takei
  • Patent number: 6887673
    Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: May 3, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure Kunkel, Subinay Ganguly, Ralph Abraham, Diane L. Hollenbaugh, Jill Rillema, Barbara Thorne, Walter W. Shuford, Robert S. Mittler
  • Patent number: 6872543
    Abstract: The present invention concerns a method for assessing the risk of peptic ulcer by determining the presence and topographic phenotype of gastritis in an individual, by determining quantitatively the pepsinogen I and gastin-17 concentrations in a serum sample from the said individual, selecting a method-specific reference value and cut-off value for respective analyte, assessing the topography and phenotype of gastritis based on a comparison of the pepsinogen I and gastrin-17 concentrations so determined with their respective method-specific reference and cut-off values, and correlating the so assessed gastritis phenotype with the risk for peptic ulcer. Preferably also Helicobacter antibodies are determined in the sample.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: March 29, 2005
    Assignee: Biohit Oyj
    Inventors: Pentti Sipponen, Matti Härkönen, Osmo Suovaniemi, Erik Forsblom
  • Patent number: 6872539
    Abstract: An analytical system for rapid detection and identification of different analytes directly from a test sample by mixing test material with a germinogenic source and enzyme-free spores, allowing the mixture to stand for a time to allow analyte-induced spore germination and subsequent de novo activity of an enzyme capable of producing a germinant in the presence of the germinogenic source and detecting the presence of a germination-derived product. The germinant which is formed promotes further spore germination with concomitant additional de novo enzyme synthesis or activation which results in a propagating cascade of analyte-independent germination after which a germination-derived product can be easily detected. The technique is particularly efficient to conduct thousands of parallel assays in an array of microscopic wells.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: March 29, 2005
    Inventor: M. Boris Rotman
  • Patent number: 6861230
    Abstract: The use of an assay for adenylate kinase in an in vitro test for the effect of external conditions on the growth characteristics of bacterial cells. Such tests in particular include tests for the sensivity of a bacteria to an antibiotic or a biostatic agent, and tests to assess the growth stage and health of the bacteria. Methods of carrying out these tests and kits for effecting them are also described and claimed.
    Type: Grant
    Filed: January 12, 1999
    Date of Patent: March 1, 2005
    Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland
    Inventors: Melanie J Murphy, Rachel L Price, David J Squirrell
  • Patent number: 6861232
    Abstract: The present invention generally relates to a method for producing biosensors and a biosensor for determination of creatinine. The biosensor comprises at least two enzymes, for the amperometric determination of enzymatically degradable substances in biological liquids, the enzymes being immobilized on a working electrode.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: March 1, 2005
    Assignee: Roche Diagnostics Operations, Inc.
    Inventor: Berhard Peter Harald Schaffar
  • Patent number: 6846646
    Abstract: The present invention relates to rapid, quantitative, specific, high through-put methods for screening test substances for their ability to inhibit activity of an ouabain-resistant Na+-K+-ATPase involved in a variety of biological processes such as regulation of osmotic balance and cell volume, maintenance of the resting membrane potential, establishment of the ionic composition of cerebrospinal fluid and aqueous humor, electrical activity of muscle and nerve, and receptor-mediated endocytosis, cardiac muscle contractility, neurotransmitter metabolism and vascular muscle cell contraction. These methods can be employed to identify compounds for use in therapeutic applications for disease processes in which dysfunction of the Na+-K+-ATPase contributes to a pathological process. The present invention also includes kits which are used in the methods provided herein.
    Type: Grant
    Filed: December 24, 1998
    Date of Patent: January 25, 2005
    Assignee: The General Hospital Corporation
    Inventor: Garner T. Haupert, Jr.
  • Patent number: 6797481
    Abstract: Methods, compositions and kits are disclosed. The methods are directed to determining the presence of one or more analytes in a sample suspected of containing any one of a plurality of the analytes. A combination is provided comprising in a medium (i) the sample, (ii) a binding partner for each of the analytes, (iii) for each of the analytes, a first reagent comprising a member of a signal producing system, a ligand and an analyte analog, and (iv) a second reagent comprising a binding partner for the ligand. The binding of the binding partner for the ligand is affected by the presence of an analyte and alters the amount of signal produced by the member of the signal producing system. The signal thus is modulated if one or more of the analytes are present in the sample. The amount of the signal is determined and is related to the presence of one or more of the analytes in the sample. The method may be homogeneous or heterogeneous.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: September 28, 2004
    Assignee: Dade Behring Marburg GmbH
    Inventors: Edwin F. Ullman, Marcel Pirio, Mary C. Ericson, Daniel B. Wagner, Dariush Davalian
  • Patent number: 6794156
    Abstract: A competitive assay to determine the presence and concentration of an intracellular analyte (e.g., cAMP) in a sample is provided. All of the steps of the assay can be performed on the same assay plate, thereby eliminating the need to transfer the cells from a tissue culture plate on which the cells are grown, induced and lysed to a separate assay plate. The assay procedure includes combining, in a reaction chamber provided with a capture antibody, an antibody for the analyte, the sample to be assayed, and a conjugate of the analyte and an enzyme such as alkaline phosphatase. The mixture is incubated and washed and an enzyme labile substrate (e.g., a chemiluminescent, fluorescent or calorimetric substrate) is added. The assay can also be performed with a tagged analyte (e.g., an analyte having a radioactive or fluorescent tag) instead of an enzyme conjugate.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 21, 2004
    Assignee: Applera Corporation
    Inventor: Anthony C. Chiulli
  • Patent number: 6787324
    Abstract: The present invention provides antibodies which specifically bind early conception factor, which can be found in body fluids of animals including but not limited to the cow, cat, dog, horse, human, sheep, and pig. The invention provides methods for detecting conception or the absence of conception in an animal, the latter being recognized by the absence of early conception factor in a suitable body fluid collected from the animal. Apparati for detecting early conception factor in a body fluid from an animal comprising the antibodies which specifically bind early conception factor are also provided.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: September 7, 2004
    Assignee: Concepto Diagnostics, Inc.
    Inventors: Nancy Tommye Jordan, John Douglas Jordan
  • Patent number: 6780600
    Abstract: Disclosed are nucleotide coding sequences and polypeptide sequences for synaptic activation binding proteins that are characterized by induction in the central nervous system following neuronal activity in rat hippocampus. Such proteins are identified by (i) substantial homology at the nucleotide or protein sequence level to specifically defined rat, human or mouse coding sequences or proteins, (ii) ability to bind to and affect the activity of effector proteins in the CNS, such as metabotropic glutamate receptors, (iii) binding specificity for a particular binding sequence, and (iv) presence in the sequence of a PDZ-like domain. Nucleotides and polypeptides of the invention are useful in screening and diagnostic assays.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: August 24, 2004
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Paul F. Worley, Paul R. Brakeman
  • Patent number: 6756198
    Abstract: An oligonucleotide useful for specific amplification of HCV RNA, or highly sensitive detection and identification of HCV RNA, and a combination thereof. A detection method using RNA amplification step, wherein the oligonucleotide of SEQ ID NO: 11 is used as a first primer and the oligonucleotide of SEQ ID NO: 6 or 7 as a second primer, the oligonucleotide of SEQ ID NO: 12 is used as a first primer and the oligonucleotide of SEQ ID NO: 7 as a second primer, or the oligonucleotide of SEQ ID NO: 13 is used as a first primer and the oligonucleotide of SEQ ID NO: 9 as a second primer.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: June 29, 2004
    Assignee: Tosoh Corporation
    Inventors: Toshiki Taya, Takahiko Ishiguro, Juichi Saito
  • Patent number: 6746841
    Abstract: There is provided a substrate for lysing calls and purifying nucleic acid having a matrix and a coating and an integrity maintainer for maintaining the purified nucleic acid. Also provided is a method of purifying nucleic acid by applying a nucleic acid sample to a substrate having an anionic detergent affixed to a matrix, the substrate physically capturing the nucleic acid, bonding the nucleic acid to a substrate and generating a signal when the nucleic acid bonds to the substrate indicating the presence of the nucleic acid. A kit for purifying nucleic acid containing a coated matrix and an integrity maintenance provider for preserving the matrix and purifying nucleic acid is also provided.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: June 8, 2004
    Assignee: Whatman Inc.
    Inventors: Galina Fomovskaia, Martin Alexander Smith, James Critser Davis, Kevin Jones, Mikhail A. Fomovsky
  • Patent number: 6740495
    Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: May 25, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung
  • Patent number: 6737244
    Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: May 18, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
  • Patent number: 6723518
    Abstract: An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa, and has a deduced isoionic point of from about pH 10.1 to about pH 10.7. Antibodies and binding portions thereof recognizing the subject chemokine and peptides which include the antigenic portions of the subject chemokines are described. DNA molecules which encode the subject chemokines as well as nucleic acid molecules which, under stringent conditions, hybridize to nucleic acid molecules encoding the subject chemokines or to a complement thereof are also disclosed.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: April 20, 2004
    Assignee: Codon Diagnostics, LLC
    Inventors: Lawrence D. Papsidero, Lyn M. Dyster, Jana M. Frustaci
  • Patent number: 6716593
    Abstract: Disclosed is a method for measuring a level of pyridinoline and/or deoxypyridinoline in a sample. In the method, a non-hydrolyzed sample containing one or more peptide-bound collagen pyridinium crosslinks selected from the group consisting of pyridinoline, deoxypyridinoline, or both, is contacted with a protease reagent under conditions effective for the protease reagent to cleave the crosslinks from attached collagen amino acids and peptides, so that peptide-bound forms are converted to native, peptide-free pyridinoline and deoxypyridinoline. After proteolysis, the level(s) of native, peptide-free pyridinoline and/or deoxypyridinoline are measured. Preferably, proteolysis is effective to ensure that at least 80% of total pyridinium crosslinks are present as the native, peptide-free forms. The method is particularly useful in screening or monitoring collagen degradation activity. Kits and reagents for use in the method are also disclosed.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: April 6, 2004
    Assignee: Quidel Corporation
    Inventors: Simon P. Robins, Jeffrey D. Brady
  • Patent number: 6699657
    Abstract: An in vitro method to conduct genomic replication of the viral genomes of viruses that utilize RNA-dependent RNA polymerase for replication (RDRP viruses), such as HCV. The method employs a construct comprising the 3′ and 5′ untranslated regions (UTRs) of the viral genome which are operably linked on the 5′ and 3′ ends of a reporter sequence, in antisense orientation, such that when viral replication is occurring within the cell which produces RDRP, the reporter protein will be made. The method of the invention provides an efficient means for measuring genomic replication in RDRP viruses, and also for the rapid screening of compounds for their ability to inhibit genomic replication of RDRP viruses, including the Hepatitis C virus (HCV).
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: March 2, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert W. King, Matthew W. Jeffries, Claudio Pasquinelli
  • Patent number: 6696264
    Abstract: The present invention relates to bioassay materials useful for the detection of toxic substances and, more particularly, to packaging materials for food and other products, along with methods for their manufacture and use. The invention provides a unique composite material capable of detecting and identifying multiple biological materials within a single package. The biological material identification system is designed for incorporation into existing types of flexible packaging material such as polyvinylchloride or polyolefin films, and its introduction into the existing packaging infrastructure will require little or no change to present systems or procedures.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: February 24, 2004
    Assignee: Toxin Alert, Inc.
    Inventors: William T. Bodenhamer, George Jackowski, Eric Davies, Mansel Griffiths